The principle behind our Medtech

Unsuspected utility of known drugs

CXS Therapeutics' own working methodology for optimized identification of the molecule of interest.

Unsuspected function

Bioinformatics identification tools

Accelerated through a transdisciplinary process using targeted exploration of several scientific databases.

Molecule identified

Meeting therapeutic needs

In diseases affecting the central nervous system, through selection of clinically relevant therapeutic targets.

Brain dopamine

Focus on  central nervous system  

A pragmatic choice


High prevalence

900,000 people suffer from Alzheimer's, 150,000 from multiple sclerosis, and around 270,000 from Parkinson.


Considerable burden

Quality of life, socio-economic costs. Ageing population and rising incidence in the under-50s.

Need for innovation

Need for innovation

Improved diagnosis, treatment, healthcare policies and support for patients and their families.

Lack of treatment

Medical needs

Only drugs aimed at slowing disease progession and controlling the symptoms.

A choice motivated by the personal history of one of the founders

"Parkinson sur Loire"

Parkinson sur Loire" challenge

Raising funds to run a first set of experiments for a disease-modifying treatment.

Creation of CXS Therapeutics

Creation of CXS Therapeutics

Provisional patent for treatment and application of research methodology to CNS diseases.

The message from Guillaume

The discovery of his pathology, the genesis of our medtech platform, his feelings as the adventure unfolded - he tells you all about it!

The advantages of  repurposing

Treating a disease with a drug from another therapeutic area. Offering new therapeutic indications to patients by addressing 4 main issues.



Already approved and proven drugs. Benefit from existing clinical safety data.



Make effective treatments available as quickly as possible for patients awaiting.



Reducing both the costs and time needed to bring a new therapy to market.



Discovering new potential for drugs used in unrelated therapeutic areas.

Application to neurological disorders

A major challenge in terms of developing effective new treatments for Alzheimer's, Parkinson's, multiple sclerosis and other central nervous system disorders. 

Chronic, incurable and disabling diseases

Parkinson's patients

Large number of patients affected

Multifactorial diseases involving complex mechanisms

Lack of effective therapies Parkinson

Lack of effective therapies

Innovative tools developed by CXS

An investigation methodology designed for optimal pharmaceutical redevelopment.



Choice of pathology of interest in the neurological field

Identification of compensating factor(s)

Pharmaceutical redevelopment of identified candidates



Correlation with expression level and identification of mechanism

Origin of major risk factor(s) and identification of a market

Molecule free of rights or unused rights


Means of implementation 

Bibliography without a priori and targeted related pathologies

Databases, experimental protocols.

Form, (co)formulation, administration : PI

Our first hit, the Parkinson's disease

Essential reminder

Parkinson's disease is the 2nd most common neurodegenerative after Alzheimer's disease.

It affects 270,000 people in FranceThis figure is rising steadily as the population ages.

It is characterized by degeneration of the dopaminergic neurons.

From a symptomatic standpoint, known clinical signs include tremorstremors slowness of movement and muscular rigidity.

Sick patient

The aim of our treatment?

The aim of current treatments is to compensate for the dopamine deficiency. In short, they aim to correct the symptoms but not to stop the mechanism at the origin of the disease. Keeping that in mind, our work aims at restoring dopaminergic production by achieving efficient neuroprotection.

Dopamine restoration

Find out more about the Parkinson's hit on SAPPIENS

SAPPIENS is a subsidiary created following the identification of this first drug candidate by CXS Therapeutics. Its objective is to carry out the pharmaceutical development of a first neuroprotective treatment, the CXS003.

Actors  behind CXS Therapeutics

Above all, a group. A complementary group, welded together and motivated by Guillaume's fight, as well as by a common desire: to offer treatments for CNS diseases where the need exists.

Guillaume Brachet

Guillaume Brachet

Hospital pharmacist, researcher and expert in biopharmaceuticals, vaccinology and pharmacology, consultant in pharmaceutical innovation.

Anthony Alioui

Anthony Alioui

PhD in genetics and molecular physiology, founder of MS PEDAGO (health promotion organization) and expert in educational engineering and communication.

Nadine Mackenzie

Nadine Mackenzie

Rheumatologist, medical director in the pharmaceutical industry for 20 years, and former member of the Management Committee of LEO Pharma France.

Philippe Nussbaumer

Philippe Nussbaumer

Expert in the creation and development of innovative companies, co-founder of the biotech company ALAXIA, co-founder of an early stage Deeptech investment fund.

Djamchid Dalili

Djamchid Dalili

Polytechnic and PhD in nuclear physics, founder of the 3W Academy (developer school), founder and CEO of medtech DIAMPARK (Parkinson disease).

Gabrielle Gache

Gabrielle Gache

Master's degree in economics and MBA (HEC). Market access and pharmaceutical Business Dev. for 30 years. Member of the Board of Directors of the Swiss licensing group from 2015 to 2022.

They are already taking part  in the adventure

Want to invest? Write to us.

Assuming you already grasped this from our approach, but therapeutic efficacy is the guarantee of our profitability.

Contact illustration